Atopic Dermatitis (Atopic Eczema) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Atopic Dermatitis (Atopic Eczema) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 10, 74, 36, 3, 98, 36 and 8 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 1, 7 and 4 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
• The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

3SBio Inc
Abate Med Inc
AbbVie Inc
Aclaris Therapeutics Inc
Adare Pharma Solutions
Akaal Pharma Pty Ltd
Akeso Inc
Alexion Pharmaceuticals Inc
Allakos Inc
Allergy Therapeutics Plc
Almirall SA
Amgen Inc
Amicogen Inc
Amorepacific Corp
Amtixbio Co Ltd
Amytrx Therapeutics Inc
Annji Pharmaceutical Co Ltd
AOBiome LLC
Apimeds Inc
Arcutis Biotherapeutics Inc
Arrien Pharmaceuticals LLC
Asana BioSciences LLC
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
AstraZeneca Plc
Atrapos Therapeutics LLC
Attillaps Holdings Inc
Avixgen Inc
Azitra Inc
Bausch Health Companies Inc
Beijing Puqi Pharmaceutical Technology Co Ltd
BenevolentAI Ltd
BioMarck Pharmaceuticals Ltd
BioMe Inc
Biomimetix JV LLC
BiomX Inc
Biosion Inc
Bioversys AG
Biozeus Pharmaceutical SA
Blueberry Therapeutics Ltd
Boehringer Ingelheim International GmbH
Boryung ViGenCell Inc
Botanix Pharmaceuticals Ltd
Brandenburg Antiinfektiva GmbH
Brexogen Inc
Brickell Biotech Inc
Bristol-Myers Squibb Co
Cellivery Therapeutics Inc
CELLnLIFE Inc
Chugai Pharmaceutical Co Ltd
Clayton Biotechnologies Inc
Clevexel Pharma SA
CSA Biotechnologies LLC
Cugene Inc
Curexsys GmbH
Cutanea Life Sciences Inc
Daiichi Sankyo Co Ltd
Derm-Biome Pharmaceuticals Inc
Dermala Inc
Dermavant Sciences Inc
DermBiont Inc
Devonian Health Group Inc
DongKoo Bio & Pharma Co Ltd
EHL Bio Co Ltd
Eli Lilly and Co
Emerald Biotechnology Espana
Enitiate Biopharmaceuticals (Hangzhou) Co Ltd
Enzychem Lifesciences Corp
Epigen Biosciences Inc
Evelo Biosciences Inc
Evommune Inc
Evotec SE
F. Hoffmann-La Roche Ltd
Galapagos NV
General Regeneratives Shanghai Ltd
Genrix (Shanghai) Biopharmaceutical Co Ltd
GI Innovation Co Ltd
GL Pharm Tech Corp
GlaxoSmithKline Plc
Hefei Medical & Pharmaceutical Co Ltd
Hill Dermaceuticals Inc
Hoth Therapeutics Inc
Huons Co Ltd
Ichnos Sciences Inc
Immune Pharmaceuticals Inc
Incyte Corp
Inflamalps SA
Ingenew Pharmaceuticals Inc
Inmagene Biopharmaceuticals Ltd
InnoCare Pharma Ltd
InnoPharmaScreen Inc
Innovation Pharmaceuticals Inc
Innovimmune Biotherapeutics Inc
Integral Molecular Inc
Intrinsic Medicine Inc
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Johnson & Johnson
Jubilant Therapeutics Inc
Jupiter Wellness Inc
JW Pharmaceutical Corp
Kangstem Biotech Co Ltd
KeyMed Biosciences Inc
Kine Sciences
Kiniksa Pharmaceuticals Ltd
KoBioLabs Inc
Krystal Biotech Inc
Kymab Ltd
Kymera Therapeutics, Inc
Kyowa Kirin Co Ltd
Landos Biopharma Inc
Lanier Biotherapeutics Inc
Larix Bioscience LLC
Lead Pharma Holding BV
Leo Pharma AS
LG Chem Ltd
Liminal BioSciences Inc
Lipidor AB
Lynk Pharmaceutical Hangzhou Co Ltd
Mabwell Shanghai Bioscience Co Ltd
Maruho Co Ltd
Matrisys Bioscience Inc
MC2 Therapeutics AS
MD Healthcare Inc
Medicenna Therapeutics Corp
Micreos BV
Midatech Pharma Plc
Minghui Pharmaceutical (Shanghai) Co Ltd
Nanjing Aimeifei Biomedical Technology Co Ltd
Nektar Therapeutics
Neovacs SA
Nepsone ehf
Neuracle Science Co Ltd
Next Science Ltd
NextPhase Therapeutics
NovaCell Technology Inc
Novan Inc
NovaRock Biotherapeutics Inc
Novartis AG
Numab Therapeutics AG
Oasis Pharmaceuticals LLC
OliX Pharmaceuticals Inc
OM Pharma Ltd
Oncocross Co Ltd
Ondek Pty Ltd
Oneness Biotech Co Ltd
Orgenesis Inc
Otsuka Pharmaceutical Co Ltd
Panolos Bioscience
Pantherics Inc
PeLeMed Co Ltd
Pfizer Inc
PrimeGen Global Inc
Principia Biopharma Inc
Provectus Biopharmaceuticals Inc
Pyramid Biosciences Inc
Qurient Co Ltd
Ralexar Therapeutics Inc
RAPT Therapeutics Inc
Regeneron Pharmaceuticals Inc
Regeneus Ltd
Regranion LLC
Rhizen Pharmaceuticals SA
Ribomic Inc
Ribon Therapeutics Inc
Rudacure Co Ltd
Sanofi
SCM lifescience Co Ltd
Seanergy Dermatology Ltd
Seelos Therapeutics, Inc.
Servatus Ltd
Shandong Boan Biotechnology Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Maiji Biotechnology Co Ltd
Shaperon Inc
Shenzhen Forward Pharmaceutical Co Ltd
Shulov Innovative Science Ltd
Signum Biosciences Inc
Signum Dermalogix Inc
Siolta Therapeutics Inc
siRNAgen Therapeutics Corp
Sosei Group Corp
StemRIM Inc
Sun Pharmaceutical Industries Ltd
Suzhou Connect Biopharmaceuticals Ltd
Suzhou Longbote Pharmaceutical Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
Technoderma Medicines Inc
Temisis Therapeutics
TeraImmune Inc
Teres Bio Inc
The Geneva Biotech Center SA
The United Laboratories International Holdings Ltd
Therabest Co Ltd
Tianjin Hemay Pharmaceutical Co Ltd
Tirmed Pharma AB
Torrent Pharmaceuticals Ltd
Transdermal Therapeutic Technologies LLC
TRPblue Inc
TWi Biotechnology Inc
UCB SA
Union Therapeutics AS
United Biomedical Inc
Vasomune Inc
vTv Therapeutics Inc
VYNE Therapeutics Inc
Welichem Biotech Inc
YIRUI Pharmaceutical Technology Co Ltd